Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 18/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14794471 | 0.91 | CHRM4 (0.64) | CHRM4CYP2C9 | |
| SCHEMBL14794724 | 0.91 | CHRM4 (0.63) | CHRM4CYP2C9MAPT | |
| SCHEMBL14794117 | 0.90 | CHRM4 (0.51) | CHRM4CYP2C9 | |
| SCHEMBL14794165 | 0.90 | CHRM4 (0.47) | CHRM4CYP2C9 | |
| SCHEMBL14794120 | 0.89 | CHRM4 (0.67) | CHRM4CYP2C9 | |
| SCHEMBL14794206 | 0.88 | CHRM4 (0.66) | CHRM4CYP2C9 | |
| SCHEMBL16273204 | 0.87 | CHRM4 (0.54) | CHRM4CYP2C9 | |
| SCHEMBL14794588 | 0.87 | CHRM4 (0.54) | CHRM4CYP2C9 | |
| SCHEMBL14794125 | 0.87 | CHRM4 (0.44) | CHRM4CYP2C9 | |
| SCHEMBL14794132 | 0.86 | CHRM4 (0.47) | CHRM4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056876-B2 | Substituted 1H-pyrazolo[3′,4′,4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| US-20140357615-A1 | SUBSTITUTED 1H-PYRAZOLO[3',4',4,5]THIENO[2,3-B]PYRIDIN-3-AMINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357615-A1 | SUBSTITUTED 1H-PYRAZOLO[3',4',4,5]THIENO[2,3-B]PYRIDIN-3-AMINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM5 | CHRM4 1/4885CYP2C9 2121/4885MAPT 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.